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Albumin solutions have been used worldwide for the treatment of critically ill patients since they became
commercially available in the 1940s. However, their use has become the subject of criticism and debate in more
recent years. Importantly, all fluid solutions have potential benefits and drawbacks. Large multicenter randomized
studies have provided valuable data regarding the safety of albumin solutions, and have begun to clarify which
groups of patients are most likely to benefit from their use. However, many questions remain related to where
exactly albumin fits within our fluid choices. Here, we briefly summarize some of the physiology and history of
albumin use in intensive care before offering some evidence-based guidance for albumin use in critically ill pa-
tients.Introduction
Albumen is doubtless one of the most important of the
animal proximate principles.
(Henry Ancell [1])
Albumin solutions have been used worldwide for the
treatment of critically ill patients since they became
commercially available in the 1940s. However, driven
largely by the results of a widely publicized meta-
analysis in 1998 that reported increased mortality rates
in patients who received albumin solutions [2], the role
of albumin administration in critically ill patients be-
came highly controversial. It is well known that albumin
has multiple physiological effects [3], including regula-
tion of colloid osmotic pressure (COP), binding and
transportation of various substances (for example, drugs,
hormones) within the blood, antioxidant properties, ni-
tric oxide modulation and buffer capabilities, which may
be of particular relevance in critically ill patients. It is
also well established that low serum albumin levels, a
common occurrence in critically ill patients, are associ-
ated with worse outcomes [4,5]. There would therefore
seem to be a good rationale for use of albumin infusions
in critically ill patients. However, albumin solutions also* Correspondence: jlvincen@ulb.ac.be
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2014have limitations, including high costs relative to possible
alternatives, notably crystalloids, and potential (rare)
risks of transmission of microorganisms, anticoagulant,
and allergic effects [6-8]. Because there are no definitive
randomized controlled trials (RCTs) demonstrating an
outcome benefit of albumin in heterogeneous groups of
critically ill patients, routine administration of albumin
for fluid resuscitation is not warranted in all patients,
but there is evidence to support its use in some patient
populations.
The purpose of this article is not to review in detail
the multiple functions and roles of albumin or the many
comparative studies and meta-analyses that have now
been performed, although we will briefly summarize this
information to provide some context. Rather, we wish to
provide some clear suggestions and guidance for albu-
min use based on the current available evidence and
highlight important areas for future research.Some background
History
Albumin was one of the first human proteins to be iso-
lated and extracted from plasma for clinical use. First crys-
tallized in 1934, a preparation was made available for
clinical use in the 1940s [9,10]. Early successful use in
multi-trauma and severely burned patients led to rapid
expansion of the so-called human albumin program in thel Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
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ting to civilian hospitals and into regular use in operating
and emergency rooms around the world. The first com-
mercially available preparations of intravenous human al-
bumin solution were developed using the cold alcohol
fractionation technique created by Edwin Joseph Cohn
[9,11]. Later developments and refinements in extraction
and processing have resulted in increasingly pure solu-
tions [12].
Physiological properties
Albumin is a natural plasma protein synthesized exclu-
sively by the liver at a rate of 9 to 14 g/day in healthy indi-
viduals, with a median half-life of about 18 to 19 days
(Figure 1) [9]. Albumin is catabolized in most organs of
the body at a similar rate of about 9 to 14 g/day, by uptake
into endocytotic vesicles on the endothelial surface [9,13];
the final breakdown products are amino acids [13].
Albumin has well-known effects on maintaining fluid bal-
ance, being responsible for 75 to 80% of COP in the basal
physiological state [9,10]. In critically ill patients, particularly
those with sepsis, the relationship between COP and the al-
bumin concentration is complex, being influenced by altered
permeability and increased transcapillary escape rates
[14,15]. Moreover, improved understanding of the endothe-
lial glyocalyx has altered our comprehension of the role of
COP in fluid balance [16]. Numerous experimental studies
have confirmed that the traditional understanding of an
inwards-directed oncotic gradient between a protein-low
interstitial space and a protein-rich plasma, as suggested by
Ernest Starling more than 100 years ago, is not correct; in-
deed, the interstitial compartment has high protein concen-
trations. Nevertheless, there is a functional vascular barrier,
created by the endothelial glycocalyx layer, a skeleton of gly-
coproteins, proteoglycans and glycosaminoglycans, and itsFigure 1 Schematic illustration of metabolism of albumin in
healthy adults. GI, gastrointestinal.interaction with plasma constituents, including albumin, to
form the endothelial surface layer, which is positioned on
the luminal side of the endothelium with a thickness of up
to 1 μm in humans [16-19]. A small space, situated on the
luminal side of the endothelium beneath this protein
sponge, is permanently cleared of passing protein molecules
by a protein-low resting flux through small breaks in the
intercellular junction strands towards the tissues [18].
Accordingly, an inwardly-directed oncotic force, quantita-
tively opposite to the hydrostatically driven fluid filtration,
develops exclusively across the small space beneath the
glycocalyx and the protein-loaded endothelial surface layer
(Figure 2).
Current understanding of optimal vascular barrier func-
tion in the high-pressure segment of the vascular system in-
cludes an intact glycocalyx combined with a minimum
concentration of plasma proteins [20]. Although albumin is
therefore a crucial part of the endothelial surface layer and
infusing albumin may seem a reasonable suggestion to
improve and maintain vascular barrier competence, experi-
ments in isolated organs have shown that the endothelial
surface layer appears to function well until the albumin con-
centration falls to a value as low as around 10 g/l [21].
Hence, the major insult when the vascular barrier fails to
function because of a severe acute illness is most probably
not hypoalbuminemia, but a breakdown of the molecular
structure of the endothelial glycocalyx because of hypervole-
mia or ischemia/reperfusion injury and other forms of
systemic inflammation [22]. Nevertheless, below a certain
threshold, artificial substitutes such as starches or gelatin are
not sufficient to form an endothelial surface layer with aFigure 2 Schematic illustration of the current understanding of
vascular barrier function within the high-pressure segment of
the vascular system. For explanation, see text. White arrows,
hydrostatic pressure (HP) gradients towards the interstitial space;
thick black arrow, inward directed oncotic force across the
endothelial surface layer; thin black arrow, small flux of protein low
ultrafiltrate. EC, endothelial cell; EG, endothelial glycocalyx; ESL,
endothelial surface layer; IS, interstitial space; PF, protein free space
beneath the endothelial surface layer; RC, red blood cell; VL,
vascular lumen.
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flow comparable with albumin [21,23].
Albumin has many other properties in addition to its
effects on intravascular volume, including transport and
antioxidant activities, but their importance in health and
disease are less well documented.
The antioxidant effects of albumin are, in brief, related
to its ability to bind certain ligands, notably iron and
copper, which reduces the availability of these compounds
for pro-oxidant reactions, and are related to an exposed
thiol group on the free cysteine residue, which acts as a
free radical scavenger, able to interact with or trap reactive
oxygen or nitrogen species, including nitric oxide, a key
mediator in many conditions including sepsis [10,24-26].
In addition to the binding of iron and copper ions, albu-
min also transports multiple other endogenous and
exogenous substances (Figure 3) [13]. Changes in albumin
concentrations and structure during critical illness can
therefore potentially have marked effects on normal homeo-
stasis and metabolism and on drug delivery and efficacy
[10,27]. In a systematic review, Ulldemolins and colleagues
reported that protein binding of antibacterials, including
ceftriaxone, ertapenem, teicoplanin, and aztreonam, was
frequently decreased in critically ill patients with hypoal-
buminemia, notably with increased volume of distribution
and drug clearance [27]. These changes could result in
suboptimal treatment, particularly for time-dependent an-
tibiotics, and may necessitate dose adjustment.
The balance of acidic to basic residues on albumin makes
it a weak acid in physiological concentrations [10,28], so that
a decrease in albumin concentration increases the anion gap.
This passively increases bicarbonate concentration, and is
therefore associated with development of metabolic alkalosis.
Albumin also has anticoagulant effects similar to, but
much less potent than, those of heparin, and inhibits
platelet aggregation [29].
Finally, albumin can protect the microvasculature and
mitigate increased vascular permeability via its antioxidant,
anti-inflammatory effects, and anti-apoptotic effects [3].Figure 3 Some of the key substances transported by albumin.
NO, nitric oxide; NSAID, nonsteroidal anti-inflammatory drug.Clearly there is much about the physiologic effects of
albumin that is not yet well understood [8]. These effects
are probably altered in various disease states, particularly
those associated with oxidant stress such as sepsis, but
whether and how these changes are involved in the
pathogenesis of these conditions requires further eluci-
dation. Administration of exogenous albumin may help
restore or provide additional antioxidant capacity, trans-
port capabilities, and vascular barrier competence, which
may account for some of the beneficial effects of albu-
min seen in specific patient populations, but it is difficult
to differentiate these from albumin’s effects on intravas-
cular volume.
Hypoalbuminemia
Hypoalbuminemia (generally defined as a serum albu-
min concentration ≤30 g/l) [5,30] is very common in
critically ill patients, the main reasons probably being in-
creased albumin losses from bleeding and via the gastro-
intestinal tract [31], increased capillary permeability
leading to a redistribution from the intravascular to the
interstitial space (previously called third-spacing) [32],
and dilution from intravenous fluid administration
Moreover, in some patients – particularly older patients
– baseline albumin levels may already be low as a result
of poor nutritional status or altered liver function. Al-
though animal models suggested that albumin synthesis
may be reduced in critical illness [33], synthesis appears
to be increased in critically ill humans [34].
Importantly, whatever the underlying mechanisms,
hypoalbuminemia is associated with worse outcomes in-
cluding increased complications [5,35-38] and reduced
short-term [5,39-43] and longer-term [42,44] survival in
critically ill patients. In a meta-analysis of 90 cohort stud-
ies that had evaluated hypoalbuminemia as a prognostic
biomarker in acutely ill patients, each 10 g/l decrease in
serum albumin concentration was associated with a 137%
increase in the odds of death, an 89% increase in morbid-
ity, and a 71% increase in length of hospital stay [5]. There
is therefore a clear association between the albumin level
and the severity of the insult [45], but it remains uncertain
whether the effect of hypoalbuminemia on outcome is a
cause–effect relationship or whether hypoalbuminemia is
rather a marker of serious disease.
Early clinical trials
For resuscitation in heterogeneous groups of critically ill
patients
Although albumin solutions were first introduced in the
1940s, the first RCT of albumin administration was only
published some 30 years later in 1975 (Table 1). This early
RCT, conducted in just 16 patients undergoing abdominal
aortic surgery, compared the effects of intraoperative use
of albumin solution with those of a sodium-rich fluid
Table 1 Key points in the albumin story so far
Year Event Reference
1941 First clinical use of human albumin solution in a patient with multiple trauma and circulatory shock [7]
1943 One of the first published reports of human albumin use in 200 patients [50]
1975 First randomized controlled trial of human albumin in 16 patients undergoing abdominal aortic surgery [46]
1998 Cochrane meta-analysis including 30 randomized controlled trials and reporting increased mortality rates in critically ill patients
who received albumin
[2]
1998 US Food and Drug Administration issued a ‘Dear Doctor’ letter to all healthcare providers expressing serious concern over the
safety of albumin administration in the critically ill population, based on the findings of the Cochrane meta-analysis, and urging
physicians to exercise discretion in its use
[51]
1999 Expert Working Party of the Committee on Safety of Medicines in UK concluded that there was insufficient evidence of harm to
warrant withdrawal of albumin products but large, purpose-designed, randomized, controlled clinical trials should be conducted
to answer questions about mortality effects
[48]
1999 Study in 126 patients with cirrhosis and spontaneous bacterial peritonitis randomized to treatment with intravenous cefotaxime or
cefotaxime and intravenous albumin; hospital and 3-month mortality rates were lower in the patients who received albumin
[52]
2001 Wilkes and Navickis’ meta-analysis including 55 trials and reporting no overall effect of albumin on mortality [53]
2003 Meta-analysis of 90 cohort studies evaluating hypoalbuminemia as an outcome predictor by multivariate analysis and nine
prospective controlled trials evaluating use of albumin to correct hypoalbuminemia; results showed hypoalbuminemia to be a
dose-dependent predictor of poor outcome and correction of serum albumin to >30 g/l associated with reduced complications
[5]
2004 Large SAFE study randomizing 6,997 patients to 4% albumin or normal saline when fluid challenge needed; results showed no
difference in mortality rates among groups, and subgroup analyses suggested benefit in patients with severe sepsis and harm in
those with traumatic brain injury
[49,54,55]
2005 US Food and Drug Administration issued a notice stating that the SAFE study had resolved the prior safety concerns raised by the
Cochrane Injuries Group in 1998
[56]
2005 Results of SOAP observational study showing that albumin use was associated with decreased mortality in critically ill patients
using a Cox proportional hazard model and a propensity case-matching analysis
[57]
2006 Pilot study of 100 patients with serum albumin ≤30 g/l randomized to receive 300 ml of 20% albumin solution on the first day
and then 200 ml/day if their serum albumin concentration remained <31 g/l, or to receive no albumin; organ function was
improved in patients treated with albumin
[30]
2011 Meta-analysis including 17 studies in patients with sepsis reporting a survival benefit for patients who received albumin [58]
2012 ESICM taskforce Consensus statement suggesting that albumin may be included in the resuscitation of severe sepsis patients
(grade 2B)
[59]
2013 Surviving Sepsis Campaign guidelines for the first time specifically suggest (grade 2C) use of albumin in the fluid resuscitation of
severe sepsis and septic shock when patients require substantial amounts of crystalloids
[60]
2013 EARSS randomized controlled multicenter study comparing 100 ml 20% albumin with normal saline in patients with early severe
sepsis, showing no differences in mortality rates between groups
[61]
2014 ALBIOS randomized controlled multicenter study comparing 20% albumin plus crystalloid or crystalloid alone and then continuing
albumin infusions to maintain serum albumin ≥30 g/l; no overall difference in 28-day or 90-day mortality rates but survival benefit
at 90 days in patients with septic shock
[62]
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less extracellular fluid expansion [46]. Other relatively
small studies followed, so that by the time the Cochrane
meta-analysis [2] was published in 1998 the average
sample size of the 32 included studies was just 46 patients.
Although the results of many studies take years to be
published and to change clinical practice – if indeed they
ever do – this Cochrane report influenced practice rapidly
around the world, especially in the UK where use of albu-
min decreased by 40 to 45% in the 6 months after publica-
tion [47]. An Expert Working Party of the Committee
on Safety of Medicines in the UK highlighted the thoughts
of many in the medical community that there was an
urgent need to conduct large multicenter RCTs to deter-
mine whether albumin administration did indeed worsenoutcomes [48]. In 2004, the results of the Saline versus Al-
bumin Fluid Evaluation (SAFE) RCT in almost 7,000 crit-
ically ill patients were published, showing that a 4%
albumin solution was as safe as normal saline when used
as a resuscitation fluid [49].
For resuscitation in patients with sepsis
Subgroup analysis of the SAFE study suggested there
may be a benefit in patients with severe sepsis (35% of
whom had septic shock), with an adjusted odds ratio for
death of 0.71 (95% CI, 0.52 to 0.97; P = 0.03) for albumin
compared with saline [54]. A subsequent meta-analysis
that included 17 RCTs comparing albumin solutions
with other fluids for fluid resuscitation in patients with
sepsis reported that albumin use was associated with
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1.0; P = 0.047) [58]. Guidelines currently suggest (grade
2C) that albumin use should be considered as a resusci-
tation fluid in patients with severe sepsis, particularly if
those patients are not responding to crystalloid infusion
[59,60], based on data from the meta-analysis [58] and
preliminary data from a multicenter study in France that
suggested a nonsignificant reduction in mortality in pa-
tients with septic shock who received albumin [61].
For resuscitation in patients with traumatic brain injury
In the SAFE trial, patients with traumatic brain injury
treated with albumin had worse outcomes than saline-
treated patients [55]. Using pattern mixture modeling,
the probable mechanism for the increased mortality ap-
peared to be albumin-induced increases in intracranial
pressure [63]. The hypotonic and hypooncotic nature of
the albumin solution used may also have played a role
[64].
For albumin replacement in patients with hypoalbuminemia
The effects of increasing albumin concentrations by giving
exogenous albumin have also been investigated in the critic-
ally ill. A meta-analysis of nine prospective controlled trials
on correcting hypoalbuminemia in acutely ill patients sug-
gested that complication rates were reduced in patients who
achieved serum albumin concentrations >30 g/l after albu-
min administration [5]. However, in a subgroup analysis of
the SAFE study in patients with hypoalbuminemia, using a
cutoff value of 25 g/l [4], there were no significant differ-
ences in outcomes in hypoalbuminemic patients and nor-
moalbuminemic patients who received albumin. In a pilot
RCT of 100 hypoalbuminemic critically ill patients who
were randomized either to receive 300 ml of 20% albumin
solution on the first day and then 200 ml/day if the serum
albumin concentration remained <30 g/dl or to receive no
albumin, Dubois and colleagues reported that organ func-
tion (as assessed by change in the Sequential Organ Failure
Assessment score) improved more in the albumin-treated
patients (P = 0.03) [30]; these patients also had a less positive
fluid balance (P =0.04). There was also a beneficial effect on
cumulative calorie intake during the first week, suggesting
that albumin may have helped decrease intestinal edema.
The effects of albumin administration may also depend
on the simultaneous use of diuretics to prevent an albu-
min infusion-induced increase in hydrostatic pressure,
which may increase (rather than decrease) edema forma-
tion. Some studies have suggested that the concurrent use
of albumin may increase furosemide-induced diuresis
in hypooncotic patients with acute respiratory distress
syndrome/acute lung injury [65,66] and cirrhosis-induced
ascites [67], although not in all critically ill patients [68];
whether this strategy has any effect on patient-centered
clinical outcomes is unclear.In 1999 Sort and colleagues published the results of a
RCT in 126 patients with cirrhosis and spontaneous bac-
terial peritonitis comparing treatment with intravenous
cefotaxime or cefotaxime plus intravenous albumin for
plasma volume expansion [52]. Renal impairment devel-
oped in fewer patients in the patients who received albu-
min (P = 0.002) and these patients also had reduced
hospital and 3-month mortality rates (both P = 0.01). A
more recent RCT reported beneficial effects of albumin
plus antibiotic on renal and circulatory function in 110
patients with cirrhosis and infections other than spon-
taneous bacterial peritonitis; treatment with albumin
was an independent predictive factor of survival [69]. A
meta-analysis of 16 RCTs also suggested that albumin
use was associated with a significant reduction in mor-
tality (odds ratio, 0.46; 95% CI, 0.25 to 0.86) and renal
impairment (odds ratio, 0.34; 95% CI, 0.15 to 0.75) in
patients with cirrhosis and any infection [70]. Two small
RCTs have also demonstrated improved renal function
in patients with cirrhosis and hepatorenal syndrome
treated with albumin and terlipressin [71,72].
Recent randomized controlled trial results
Following the results of the SAFE study suggesting a
benefit of albumin administration in patients with sepsis,
several groups designed RCTs to further evaluate albu-
min use in this specific group of patients.
In the ALBIOS study, conducted in 100 ICUs in Italy
[62], 1,818 patients with severe sepsis or septic shock were
randomized either to receive 300 ml of 20% albumin plus
crystalloid or to receive crystalloid alone initially to achieve
the target resuscitation goals of the early goal-directed ther-
apy protocol used by Rivers and colleagues [73]. Over the
subsequent 28 days, albumin infusions were adjusted to
maintain serum albumin ≥30 g/l; crystalloid solutions were
given when considered clinically indicated by the attending
physician. More patients in the albumin group than in the
crystalloid group reached the target mean arterial pressure
within 6 hours after randomization (86% versus 82.5%, P =
0.04), and during the first 7 days the mean arterial pressure
was higher and the net fluid balance lower in the albumin
group than in the crystalloid group [62], despite similar
amounts of fluid being administered to the two groups.
There were, however, no overall differences in 28-day mor-
tality rates (32% albumin vs 32% crystalloid; relative risk in
the albumin group, 1.00; 95% CI, 0.87 to 1.14; P = 0.94) or
90-day mortality rates (41% albumin vs 44% crystalloid;
relative risk, 0.94; 95% CI, 0.85 to 1.05; P = 0.29) between
the groups. Of the 1,818 patients, 579 (31.8%) were ran-
domized within 6 hours and 1,239 (68.2%) more than 6
hours after meeting the clinical criteria for severe sepsis;
there were no significant differences in outcomes according
to the interval between meeting clinical criteria and
randomization. In the subgroup of patients with septic
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ceived albumin had significantly lower 90-day mortality
rates than those who received saline (44% versus 50%; rela-
tive risk, 0.87; 95% CI, 0.77 to 0.99; P = 0.03) [62].
In the multicenter EARSS study in France, so far published
only in abstract form [61], 798 patients with septic shock of
less than 6 hours duration were randomized to receive 100
ml of 20% albumin or 100 ml of 0.9% saline every 8 hours
for 3 days. Almost all patients had severe hypoalbuminemia
at study inclusion. There were no significant differences in
mortality rates between the two groups (24.1 vs 26.3%).
Where next?
Having briefly reviewed the background to the albumin
story so far, where are we left? Who, if anyone, should
be given albumin? Some answers will be provided from
further analysis of the results from recent and ongoing
studies, but in the meantime we believe there are six key
questions that need answering.
Resuscitation versus supplementation (medication)?
Initially considered largely as an acute resuscitation fluid for
its beneficial short-term effects on COP and blood volume,
recognition of the adverse outcomes associated with hypoal-
buminemia and new knowledge about vascular barrier func-
tioning has led to an increased interest in use of albumin
solutions as a supplement to correct and maintain albumin
levels. Nevertheless, it is difficult to separate volume effects
from the effects of maintenance of serum albumin – par-
ticularly in critically ill patients, many of whom are hypoal-
buminemic and in whom it is difficult to clearly relate the
timing of interventions to the onset of disease. Thus, most
studies of albumin administration actually combine a degree
of resuscitation with a degree of supplementation/mainten-
ance of serum albumin. As a resuscitation fluid, the major
benefit of albumin will be from its impact on COP, resulting
in a short-term increase in intravascular volume. As supple-
mentation, effects on COP are also important, potentially re-
ducing the risk of interstitial edema, but some of albumin’s
other actions, such as transport and antioxidant effects, may
also become important.
Efforts to substitute synthetic colloids for albumin as
part of perioperative fluid therapy have not been very
successful. Hydroxyethylstarch solutions can persist for
long durations in the skin, the liver and, most import-
antly, the kidney [74], with a potential risk of renal fail-
ure and even increased mortality rates in septic patients
[75]. Gelatin solutions have been less well studied, in
part because they are not available in the United States,
and their persistence is quite short.
Which concentration of albumin solution?
Albumin solutions are available in a variety of concentra-
tions, mainly 20 to 25% or 4 to 5%, and which concentrationshould be used has generated some debate. Direct blood
volume measurements in humans have revealed that the
intravascular volume effect of isooncotic preparations of
human albumin solutions is much higher than that of crys-
talloids (>80% vs <20%) [76]. However, the albumin concen-
tration chosen largely depends on whether other fluids,
especially crystalloids, are administered simultaneously – a
20% (20 g in 100 ml) albumin solution given simultaneously
with 500 ml of normal saline solution is equivalent to a 3.3%
(20/600) albumin solution. Nevertheless, hyperoncotic albu-
min may be a better choice if edema is already present [77],
avoiding excessive sodium and chloride loads and their at-
tendant complications [78].
Which dose of albumin?
Determining the ideal dose or volume of albumin that
should be used is difficult. Early physiological studies
demonstrated that administration of 5% albumin to septic
patients expanded the plasma volume by an amount
equivalent to the volume infused [79]. Different studies
have used different doses, and perhaps the dose should be
adjusted according to a target serum albumin concentra-
tion, as in the ALBIOS study [62]. The dose chosen by
Mira and colleagues in the EARSS study (100 ml of 20%
albumin 8 hourly for 3 days) achieved an increase in
serum albumin to 25 to 29 g/l [61], raising the possibility
that the albumin dose used may have been too low to
show definite benefit – although this increase was similar
to that reported in the SAFE study subgroup analysis of
patients with sepsis, in whom a benefit was reported [54].
Should albumin infusions target albumin levels?
The need to make decisions as to whether or not a par-
ticular patient should receive albumin based on their albu-
min level is related to whether the considered use is
targeted as resuscitation or supplementation. Most pa-
tients requiring resuscitation fluids in the ICU are hypoal-
buminemic and, as mentioned earlier, the fluid will be
given largely for its effects on COP – that is, limiting
edema formation – provided that the hydrostatic pressure
does not increase excessively. In such patients, monitoring
the albumin concentration is probably of little value.
In more prolonged administration as supplementation,
however, serum albumin levels may be a useful guide to
ongoing needs, in combination with disease severity,
hemodynamic status, and nutritional status; just as an ar-
bitrary cutoff hemoglobin concentration should not be
used to define absolute need for blood transfusion in all
patients, so a specific serum albumin threshold for albu-
min administration is unlikely to be relevant to all. The
meta-analysis of nine prospective controlled trials on cor-
recting hypoalbuminemia in acutely ill patients mentioned
earlier suggested that complication rates were reduced in
patients who achieved serum albumin concentrations >30
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ALBIOS study protocol stipulated that albumin adminis-
tration should be titrated to maintain serum albumin ≥30
g/l [62]. Albumin levels were measured on a daily basis
and 200 or 300 ml of 20% albumin were administered in
patients with albumin levels between 25 and 30 g/l or <25
g/l, respectively. Following the time course of albumin
levels, especially in response to an albumin infusion, may
be more valuable than a single albumin level, but optimal
albumin levels during critical illness are not clearly
defined.
What type of albumin preparation?
Currently available human albumin solutions are devel-
oped using various techniques, such that the various com-
mercially available albumin solutions may differ in protein
content and composition, binding capacity, metal ion con-
tent, antioxidant properties, charge, capacity to bind
drugs, and so forth [80,81]. This is a difficult topic to
evaluate because there are few data available about the
precise composition of the different albumin solutions
and whether or how this may impact on its clinical prop-
erties [81,82], but the differences may help explain some
of the different study results. One study comparing six dif-
ferent commercially available preparations of albumin
with serum albumin from healthy volunteers reported
large differences between the solutions, particularly in
terms of the presence of oxidized cysteine 34 (23% in hu-
man volunteer albumin vs 54 to 60% in commercial prep-
arations) [81], which may influence the properties and
hence the clinical impact of albumin solutions [82]. Pre-
cise compositions of albumin solution should be clearly
identified in future study reports.
Is albumin cost-effective?
Albumin solutions have a good safety record [83]. The
large SAFE study reported that 4% albumin was as safe
as normal saline in a heterogeneous group of ICU pa-
tients [49] and meta-analyses have noted that albumin
has a better safety profile than other colloid solutions
[84,85]. Reports of adverse events, including anticoagu-
lant and allergic effects and transmission of microorgan-
isms, are rare. In a study evaluating adverse event
reporting between 1998 and 2000, the incidence of all
reported serious nonfatal and fatal adverse events was
just 5 per million doses, and no patient death was classi-
fied as probably related to albumin administration [83].
Albumin is, however, more costly than all other resus-
citation fluids, although prices have decreased relative
to other fluids over the last 10 years. Nevertheless,
if shown to reduce morbidity and mortality even by
a small amount, it is likely that the cost-effectiveness
ratio would favor albumin because so many ICU inter-
ventions are very costly. There have been very few cost-effectiveness evaluations of albumin use in the ICU.
Guidet and colleagues assessed the cost-effectiveness of
albumin as given in the SAFE study on patients with se-
vere sepsis and septic shock admitted to one of 35
French ICUs [86]. Based on a presumed 4.6% reduction
in mortality associated with albumin therapy (as shown
in the SAFE study), 513 lives were saved among the
11,137 patients included, with an estimated life expect-
ancy for each life saved of 9.8 years. The cost per life
saved was estimated at €6,037 and the cost per life-year
saved as €617. The authors therefore concluded that al-
bumin administration was a cost-effective intervention
in patients with severe sepsis or septic shock [86]. Most
recently, a cost-effectiveness analysis in severe sepsis and
septic shock using an advanced Bayesian approach ob-
served life-years gained with albumin relative to crystal-
loid therapy, and concluded that albumin may be the
most cost-effective intravenous solution in this patient
population [87].
Recommendations and conclusions
Many changes within intensive care medicine have come
as the result of the realization that traditional practices
once thought to be therapeutic were in fact detrimental
[88]. Human albumin solutions have been available for
almost 60 years and provide effective resuscitation with less
fluid required than for crystalloid solutions; for many years,
however, albumin was widely and perhaps nondiscrimi-
nantly used as a resuscitation fluid with little realization
that it may not be appropriate in all patients. Although
criticized for its methodology and the heterogeneity of the
studies included, the 1998 Cochrane meta-analysis brought
this possibility to the attention of the wider community
and stimulated the conduct of large, multicenter RCTs [2].
As the results of these studies become available, the role of
albumin in today’s critical care unit is becoming clearer
and several recommendations can be made:
 Albumin administration, although unlikely to cause
harm in most patients, is not necessary in all
critically ill patients and should be reserved for use
in specific groups of patients in whom there is
evidence of benefit.
 A hypotonic albumin solution should be avoided as
a resuscitation fluid in patients with traumatic brain
injury, based on the results of the SAFE subgroup
analysis [55].
 There is now enough evidence – albeit largely from
subgroup analyses – and plausible biological
rationale to support use of albumin in patients with
septic shock when a colloid is considered [54,62].
 Albumin administration should be considered in
patients with cirrhosis and spontaneous bacterial
peritonitis [52], but possibly also other infections
Vincent et al. Critical Care Page 8 of 102014, 18:231
http://ccforum.com/content/18/4/231[69,70]; in hypooncotic patients with acute
respiratory distress syndrome [65,66]; and also in
patients with cirrhosis and type 1 hepatorenal
syndrome [89].
Future research should be focused on patients who are
most likely to benefit from albumin administration in whom
the evidence is inadequate or controversial because of con-
flicting study results. In addition to observational cohort
studies and RCTs focusing on specific patient groups, mech-
anistic studies are necessary to further elucidate the molecu-
lar and physiologic rationale for the beneficial effects of
albumin and explore how albumin’s pleiotropic actions may
be important in specific groups of critically ill patients. Such
studies also need to better elucidate the mechanisms of
development of hypoalbuminemia. Studies also need to clar-
ify issues of dosage and appropriate targets and whether dif-
ferent albumin solutions have unique differential effects on
patients’ responses and outcomes to albumin administra-
tion. The effects of albumin infusions on drug (especially
antimicrobial) dosing also need clarification.
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